[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615833":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":75,"collaborators":77,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":19,"eligibilityCriteria":87,"healthyVolunteers":84,"sex":88,"minAge":89,"maxAge":19,"enrollmentInfo":90,"targetDuration":19,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":107,"whyStopped":19,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Changi General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hybrid hormones","EXPERIMENTAL","Previous studies have shown that hybrid hormones are elevated in patients with unilateral primary aldosteronism who have large, visible adenomas in their adrenal glands. These tumors harbour a somatic KCNJ5 mutation and are also most likely to be cured of hypertension after surgery.\n\nHence, the investigators hypothesize that high hybrid hormones levels, in the presence of an adenoma on a computed tomography imaging would identify study participants who can proceed to surgery.",[13],"Diagnostic Test: Hybrid hormones",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Participants will have a baseline blood sample taken so the investigators can measure the adrenal steroid biomarkers 18-oxocortisol, 18-hydroxylcortisol and other steroids.\n\nThe collected plasma or serum will then be analyzed in the laboratory using validated methods, such as liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS), to determine the levels of these biomarkers.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Troy Puar, FRCP, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Troy H Puar, FRCP, PhD","CONTACT","67888833","troy_puar@cgh.com.sg",[31,45,55,65],{"facility":5,"status":19,"city":32,"state":32,"zip":33,"country":32,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Singapore","529889","SG",{"type":36,"coordinates":37},"Point",[38,39],103.85007,1.28967,{"lat":39,"lon":38},[42,44],{"name":26,"role":27,"phone":43,"phoneExt":19,"email":29},"+65 68503967",{"name":26,"role":23,"phone":19,"phoneExt":19,"email":19},{"facility":46,"status":19,"city":32,"state":19,"zip":19,"country":32,"countryCode":34,"cosmosGeoPoint":47,"geoPoint":49,"contacts":50},"National University Hospital",{"type":36,"coordinates":48},[38,39],{"lat":39,"lon":38},[51],{"name":52,"role":27,"phone":53,"phoneExt":19,"email":54},"Ada Teo","6908 2222","ada_ed_teo@nuhs.edu.sg",{"facility":56,"status":19,"city":32,"state":19,"zip":19,"country":32,"countryCode":34,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Sengkang General Hospital",{"type":36,"coordinates":58},[38,39],{"lat":39,"lon":38},[61],{"name":62,"role":27,"phone":63,"phoneExt":19,"email":64},"Matthew Chuah","6930 5000","matthew.chuah@singhealth.com.sg",{"facility":66,"status":19,"city":32,"state":19,"zip":19,"country":32,"countryCode":34,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"Singapore General Hospital",{"type":36,"coordinates":68},[38,39],{"lat":39,"lon":38},[71],{"name":72,"role":27,"phone":73,"phoneExt":19,"email":74},"Swee Du Soon","6222 3322","swee.du.soon@singhealth.com.sg",{"type":76,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[78,79,80],{"name":66,"class":6},{"name":56,"class":6},{"name":81,"class":6},"National University Hospital, Singapore","100615833","trial-of-aldosterone-hybrid-steroid-for-guiding-curable-treatment-of-primary-aldosteronism-target-pa-100615833",false,"NCT07297745","Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)","Inclusion Criteria:\n\n* Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.\n* Willing to undergo subtype testing with adrenal vein sampling and\u002For molecular imaging (Positron Emission Tomography\u002FComputed Tomography, PET\u002FCT).\n* Keen for surgical treatment if shown to have unilateral primary aldosteronism.\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.","ALL","21 Years",{"count":91,"type":92},120,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.",[98,99],"Hyperaldosteronism; Primary","Primary Aldosteronism Due to Aldosterone Producing Adenoma",[101,102,103,104,105,106],"Hybrid hormone","Subtyping","adrenalectomy","adrenal vein sampling","biomarkers","steroid profiling","NOT_YET_RECRUITING","2026-01-07",{"date":110,"type":111},"2026-01-09","ACTUAL",{"date":113,"type":92},"2026-01-15",{"date":115,"type":92},"2029-12-31",{"name":5,"class":6},4]